Catalyst Wire Dossier Catalyst Wire Dossier
EMA approval · 2025-05-23

EMA Authorised: Ifirmasta (previously Irbesartan Krka) (irbesartan hydrochloride) — Krka, d.d., Novo mesto

View source ↗

Summary

EMA has authorised Ifirmasta (irbesartan hydrochloride) by Krka for the treatment of hypertension. It is an authorised generic version of irbesartan hydrochlori…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ifirmasta (irbesartan hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Hypertension. MAH: Krka, d.d., Novo mesto. Decision date: 08/05/2025